Hippo Signaling Disruption

Phosphorylation by MST1/2 and LATS1/2 determines whether YAP and TAZ can promote transcription. When these kinases phosphorylate the coactivators, the proteins are retained in the cytoplasm or directed toward degradation. Reduced phosphorylation removes those restraints, allowing nuclear accumulation and subsequent gene activation. This switch links kinase pathway status to control of proliferation, survival, and tissue growth.

Nuclear YAP and TAZ serve as transcriptional coactivators once they enter the nucleus. By partnering with TEAD factors, they help activate genes associated with growth and cell survival. This interaction explains why reduced pathway restraint can have broad effects beyond protein localization alone: it changes the transcriptional program of the cell. TEAD-linked transcription is therefore relevant to understanding dysregulated growth.

Persistence matters because continued pathway dysregulation can maintain growth and survival signaling. In disease biology, this sustained state is associated with cancer and fibrosis and can also disturb normal regenerative responses. The medical concern is that an altered growth-control pathway may become a continuing driver of abnormal tissue behavior rather than remaining a limited signaling change.

A pathway-focused assessment can examine linked changes in MST1/2 and LATS1/2 control, YAP and TAZ phosphorylation, their cytoplasmic retention or degradation, and their movement into the nucleus. It can also consider activation of TEAD-associated growth and survival genes. Together, these observations connect pathway status with the transcriptional and cellular consequences of disrupted growth control.

The pathway provides several biologically connected features that may inform biomarker development, including kinase-mediated control of YAP and TAZ, their cellular localization or degradation, and TEAD-associated transcription. Evaluating these features can help characterize whether growth-control signaling is altered in disease. Such information may support studies that distinguish pathway dysregulation and relate it to cancer, fibrosis, or abnormal regeneration.

Two broad therapeutic directions follow from the pathway mechanism: restoring growth control upstream or inhibiting YAP/TAZ-driven transcription downstream. Restoring pathway restraint could limit nuclear access or persistence of the coactivators, while targeting their transcriptional activity could reduce activation of growth and survival genes. These strategies are relevant to investigating treatments for cancer, fibrosis, and abnormal regenerative processes.